Dual role of complement in tumour growth and metastasis (Review)

International Journal of Molecular Medicine

Volumn 25, Issue 3, 2010, Pages 307-313

  Stover, Cordula ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

Author keywords

Complement; Inflammation; Tumour injury

Indexed keywords

BETA GLUCAN; BEVACIZUMAB; CATHEPSIN; CETUXIMAB; COMPLEMENT; COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3 RECEPTOR; COMPLEMENT COMPONENT C5A; DECAY ACCELERATING FACTOR; DECAY ACCELERATING FACTOR ANTIBODY; GLYCOPROTEIN; HEPARAN SULFATE; HISTIDINE RICH GLYCOPROTEIN; LOW MOLECULAR WEIGHT HEPARIN; MONOCLONAL ANTIBODY; THROMBOSPONDIN; TOLL LIKE RECEPTOR; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN EXPRESSION; CD8+ T LYMPHOCYTE; CELL HYPOXIA; CELL INFILTRATION; COMPLEMENT ACTIVATION; COMPLEMENT DEPENDENT CYTOTOXICITY; COMPLEMENT SYSTEM; HUMAN; IMMUNOGENICITY; IMMUNOSURVEILLANCE; INFLAMMATION; INFLAMMATORY CELL; INNATE IMMUNITY; LUNG CANCER; LUNG NON SMALL CELL CANCER; METASTASIS; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; REVIEW; TUMOR CELL; TUMOR CELL DESTRUCTION; TUMOR GROWTH; TUMOR IMMUNITY;

ANIMALS; ANTIBODIES, MONOCLONAL; COMPLEMENT SYSTEM PROTEINS; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOLOGIC SURVEILLANCE; NEOPLASM METASTASIS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 76949084436     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm_00000346     Document Type: Review

References (89)

1. Liszewski M, Fang C and Atkinson J: Inhibiting complement activation on cells at the step of C3 cleavage. Vaccine 26 (Suppl 8): 122-127, 2008.
2. Fearon D and Carroll M: Regulation of B lymphocyte responses to foreign and self-antigens by the CD19/CD21 complex. Annu Rev Immunol 18: 393-422, 2000.
3. Kemper C and Atkinson J: T-cell regulation: with complements from innate immunity. Nat Rev Immunol 7: 9-18, 2007.
4. Longhi MP, Harris C, Morgan B and Gallimore A: Holding T cells in check - a new role for complement regulators? Trends in Immunol 27: 102-108, 2006.
5. Reis E, Barbuto J, Köhl J and Isaac L: Impaired dendritic cell differentiation and maturation in the absence of C3. Mol Immunol 45: 1952-1962, 2008.
6. Fernandez Gonzalez S, Jayasekera J and Carroll M: Complement and natural antibody are required in the long-term memory response to influenza virus. Vaccine 26 (Suppl 8): 186-193, 2008.
7. Huflejt M, Vuskovic M, Vasiliu D, Xu H, Obukhova P, Shilova N, Tuzikov A, Galanina O, Arun B, Lu K and Bovin N: Anticarbohydrate antibodies of normal sera: findings, surprises and challenges. Mol Immunol 46: 3037-3049, 2009.
8. Gancz D and Fishelson Z: Cancer resistance to complement-dependent cytotoxiciy (CDC): Problem-oriented research and development. Mol Immunol 46: 2794-2800, 2009.
9. Kim D, Martin C, Lee S and Martin B: Expression of complement protein C5a in a murine mammary cancer model: tumor regression by interference with the cell cycle. Cancer Immunol Immunother 54: 1026-1037, 2005.
10. Sjöberg A, Trouw L and Blom A: Complement activation and inhibition: a delicate balance. Trends Immunol 30: 83-90, 2008.
11. Cotter T: Apoptosis and cancer: the genesis of a research field. Nature Rev Cancer 9: 501-507, 2009.
12. Morgan J, Spendlove I and Durrant L: The role of CD55 in protecting the tumour environment from complement attack. Tissue Antigens 60: 213-223, 2002.
13. Mikesch J-H, Buerger H, Simon R and Brandt B: Decay-accelerating factor (CD55): A versatile acting molecule in human malignancies. Biochim Biophys Acta 1766: 42-52, 2006.
14. Kusama T, Miyagawa S, Moritan T, Kubo T, Yamada M, Sata H, Fukuta D, Matsunami K and Shirakura R: Downregulation of NK cell-mediated swine endothelial cell lysis by DAF (CD55). Transplant Proc 35: 529-530, 2003.
15. Liu J, Miwa T, Hilliard B, Chen Y, Lambris J, Wells A and Song W-C: The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo. J Exp Med 201: 567-577, 2005.
16. Zhang X, Kimura Y, Fang C, Zhou L, Sfyroera G, Lambris JD, Wetsel RA, Miwa T and Song W-C: Regulation of Toll-like receptor-mediated inflammatory response by complement in vivo. Blood 110: 228-236, 2007.
17. Varela J, Imai M, Atkinson C, Ohta R, Rapisardo M and Tomlinson S: Modulation of protective T cell immunity by complement inhibitor expression on tumor cells. Cancer Res 68: 6734- 6742, 2008.
18. Kilgore K, Schmid E, Shanley T, Flory C, Maheswari V, Tramontini N, Cohen H, Ward P, Friedl H and Warren J: Sublytic concentrations of the membrane attack complex of complement induce endothelial interleukin-8 and monocyte chemoattractant protein-1 through nuclear factor-kappa B activation. Am J Pathol 150: 2019-2031, 1997.
19. Reiter Y, Ciobotariu A and Fishelson Z: Sublytic complement attack protects tumor cells from lytic doses of antibody and complement. Eur J Immunol 22: 1207-1213, 1992.
20. Markiewski M, DeAngelis R, Benencia F, Ricklin-Lichtsteiner S, Koutoulaki A, Gerard C, Coukos G and Lambris J: Modulation of the antitumor immune response by complement. Nat Immunol 9: 1225-1235, 2008.
21. Orr F, Mokashi S and Delikatny J: Generation of a complement-derived chemotactic factor for tumor cells in experimentally induced peritoneal exudates and its effect on the local metastasis of circulating tumor cells. Am J Pathol 108: 112-118, 1982.
22. Dolcetti L, Marigo I, Mantelli B, Peranzoni E, Zanovello P and Bronte V: Myeloid-derived suppressor cell role in tumor-related inflammation. Cancer Lett 267: 216-225, 2008.
23. Lee HM, Wu W, Wysoczynski M, Liu R, Zuba-Surma EK, Kucia M, Ratajczak J and Ratajczak MZ: Impaired mobilization of hematopoietic stem/progenitor cells in C5-deficient mice supports the pivotal involvement of innate immunity in this process and reveals novel promobilization effects of granulocytes. Leukemia 23: 2052-2062, 2009.
24. Lalli P, Strainic M, Lin F, Medof M and Heeger P: Decay accelerating factor can control T cell differentiation into IFN-γ-producing effector cells via regulating local C5a-induced IL-12 production. J Immunol 179: 5793-5802, 2007.
25. Kuraya M, Ming Z, Liu X, Matsushita M and Fujita T: Specific binding of L-ficolin and H-ficolin to apoptotic cells leads to complement activation. Immunobiology 209: 689-697, 2005.
26. Schwartz-Albiez R, Laban S, Eichmüller S and Kirschfink M: Cytotoxic natural antibodies against human tumours: An option for anti-cancer immunotherapy? Autoimmun Rev 7: 491-495, 2008.
27. Wasiuk A, de Vries V, Hartmann K, Roers A and Noelle R: Mast cells as regulators of adaptive immunity to tumours. Clin Exp Immunol 155: 140-146, 2008.
28. Brandeis W, Tan C, Wang Y, Good R and Day N: Circulating immune complexes, complement and complement component levels in childhood Hodgkin's disease. Clin Exp Immunol 39: 551-561, 1980.
29. Gropp C, Havemann K, Scherfe T and Ax W: Incidence of circulating immune complexes in patients with lung cancer and their effect on antibody-dependent cytotoxicity. Oncology 37: 71-76, 1980.
30. Di Gaetano N, Cittera E, Nota R, Vecchi A, Grieco V, Scanziani E, Botto M, Introna M and Golay J: Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 171: 1581-1587, 2003.
31. Macor P and Tedesco F: Complement as effector system in cancer immunotherapy. Immunol Lett 111: 6-13, 2007.
32. DeNardo DG and Coussens LM: Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res 9: 212-222, 2007.
33. Lin W-W and Karin M: A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 117: 1175-1183, 2007.
34. Lucas S, Karlsson-Parra A, Nilsson B, Grimelius L, Åkerström G, Rastad J and Juhlin C: Tumor-specific depostion of immunoglobulin G and complement in papillary thyroid carcinoma. Hum Pathol 27: 1329-1335, 1996.
35. Ostrand-Rosenberg S and Sinha P: Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol 182: 4499-4506, 2009.
36. Marigo I, Dolcetti L, Serafini P, Zanovello P and Bronte V: Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev 222: 162-179, 2008.
37. Johansson M, DeNardo D and Coussens L: Polarized immune responses differentially regulate cancer development. Immunol Rev 222: 145-154, 2008.
38. Sikkeland LI, Thorgersen EB, Haug T and Mollnes TE: Complement activation and cytokine response by BioProtein, a bacterial single cell protein. Clin Exp Immunol 148: 146-152, 2007.
39. Tolsma SS, Volpert OV, Good DJ, Frazier WA, Polverini PJ and Bouck N: Peptides derived from two separate domains of the matrix protein thrombospondin-1 have anti-angiogenic activity. J Cell Biol 122: 497-511, 1993.
40. Prater C, Plotkin J, Jaye D and Frazier W: The properdin-like type I repeats of human thrombospondin contain a cell attachment site. J Cell Biol 112: 1031-1040, 1991.
41. Pattrick M, Luckett J, Yue L and Stover C: Dual role of complement in adipose tissue. Mol Immunol 46: 755-760, 2009.
42. Liu D, Shriver Z, Venkataraman G, El Shabrawi Y and Sasisekharan R: Tumor cell surface heparan sulfate as cryptic promoters or inhibitors of tumor growth and metastasis. Proc Natl Acad Sci USA 99: 568-573, 2002.
43. Kemper C, Mitchell L, Zhang L and Hourcade D: The complement protein properdin binds apoptotic T cells and promotes complement activation and phagocytosis. Proc Natl Acad Sci 105: 9023-9028, 2008.
44. Kuderer NM, Ortel TL and Francis CW: Impact of venous thromboembolism and anticoagulation on cancer and cancer survival. J Clin Oncol 27: 4902-4911, 2009.
45. Gerotziafas GT, Papageorgiou C, Hatmi M, Samama MM and Elalamy I: Clinical studies with anticoagulants to improve survival in cancer patients. Pathophysiol Haemost Thromb 36: 204-211, 2008.
46. Almeda S, Rosenberg RD and Bing DH: The binding properties of human complement component C1q. Interaction with mucopolysaccharides. J Biol Chem 258: 785-791, 1983.
47. Caldwell EE, Andreasen AM, Blietz MA, Serrahn JN, Van der Noot V, Park Y, Yu G, Linhardt RJ and Weiler JM: Heparin binding and augmentation of C1 inhibitor activity. Arch Biochem Biophys 361: 215-222, 1999.
48. Casu B, Vlodavsky I and Sanderson RD: Non-anticoagulant heparins and inhibition of cancer. Pathophysiol Haemost Thromb 36: 195-203, 2008.
49. Mousa SA, Linhardt R, Francis JL and Amirkhosravi A: Anti-metastatic effect of a non-anticoagulant low-molecular-weight heparin versus the standard low-molecular-weight heparin, enoxaparin. Thromb Haemost 96: 816-821, 2006.
50. Irigoyen M, Ansó E, Martínez E, Garayoa M, Martínez-Irujo J and Rouzaut A: Hypoxia alters the adhesive properties of lymphatic endothelial cells. A transcriptional and functional study. Biochim Biophys Acta 177: 880-890, 2007.
51. Okroj M, Corrales L, Stokowska A, Pio R and Blom A: Hypoxia increases susceptibility of non-small cell lung cancer cells to complement attack. Cancer Immunol Immunother 58: 1773-1782, 2009.
52. Shi X, Zhang B, Zhang J, Wang G and Gao M: CD59 silencing via retrovirus-mediated RNA interference enhance complement-mediated cell damage in ovary cancer. Cell Mol Immunol 6: 61-66, 2009.
53. Zell S, Geis N, Rutz R, Schultz S, Giese T and Kirschfink M: Down-regulation of CD55 and CD46 expression by anti-sense phosphorothioate oligonucleotides (S-ODNs) sensitizes tumour cells to complement attack. Clin Exp Immunol 150: 576-584, 2007.
54. Saldova R, Wormald M, Dwek R and Rudd P: Glycosylation changes on serum glycoproteins in ovarian cancer may contribute to disease pathogenesis. Dis Markers 25: 219-232, 2008.
55. Qiu Y, Patwa TH, Xu L, Shedden K, Misek DE, Tuck M, Jin G, Ruffin MT, Turgeon DK, Synal S, Bresalier R, Marcon N, Brenner DE and Lubman DM: Plasma glycoprotein profiling for colorectal cancer biomarker identification by lectin glycoarray and lectin blot. J Proteome Res 7: 1693-1703, 2008.
56. Frade R, Rodrigues-Lima F, Huang S, Xie K, Guillaume N and Bar-Eli M: Procathepsin-L, a proteinase that cleaves human C3 (the third component of complement), confers high tumorigenic and metastatic properties to human melanoma cells. Cancer Res 58: 2733-2736, 1998.
57. Rozanov D, Savinov A, Golubkov V, Tomlinson S and Strongin A: Interference with the complement system by tumor cell membrane type-1 matrix metalloproteinase plays a significant role in promoting metastasis in mice. Cancer Res 66: 6258-6263, 2006.
58. Loberg R, Day L, Dunn R, Kalikin L and Pienta K: Inhibition of Decay-accelerating factor (CD55) attenuates prostate cancer growth and survival in vivo. Neoplasia 8: 69-78, 2006.
59. Hawlisch H, Belkaid Y, Baelder R, Hildeman D, Gerard C and Köhl J: C5a negatively regulates toll-like receptor 4-induced immune responses. Immunity 22: 415-426, 2005.
60. Zhou X, Hu W and Qin X: The role of complement in the mechanism of action of rituximab for B-cell lymphoma: implications for therapy. Oncologist 13: 954-966, 2008.
61. Korbelik M and Cecic I: Complement activation cascade and its regulation: relevance for the response of solid tumors to photodynamic therapy. J Photochem Photobiol B 93: 53-59, 2008.
62. Sivasankar B, Longhi MP, Gallagher K, Betts G, Morgan BP, Godkin A and Gallimoore A: CD59 blockade enhances antigen-specific CD4+ T cell responses in humans: a new target for cancer immunotherapy. J Immunol 182: 5203-5207, 2009.
63. Yan J, Allendorf D, Li B, Yan R, Hansen R and Donev R: The role of membrane complement regulatory proteins in cancer immunotherapy. Adv Exp Med Biol 632: 159-174, 2008.
64. Durrant LG, Chapman MA, Buckley DJ, Spendlove I, Robins RA and Armitage NC: Enhanced expression of the complement regulatory protein CD55 predicts a poor prognosis in colorectal cancer patients. Cancer Immunol Immunother 52: 638-642, 2003.
65. Durrant L and Spendlove I: Immunization against tumor cell surface complement-regulatory proteins. Curr Opin Investig Drugs 2: 959-966, 2001.
66. Liu Y, Chen L, Peng S, Chen Z, Gimm O, Finke R and Hoang-Vu C: The expression of CD97EGF and its ligand CD55 on marginal epithelium is related to higher stage and depth of tumor invasion of gastric carcinomas. Oncol Rep 14: 1413-1420, 2005.
67. Holla V, Wang D, Brown J, Mann J, Katkuri S and DuBois R: Prostaglandin E2 regulates the complement inhibitor CD55/Decay-accelerating factor in colorectal cancer. J Biol Chem 280: 476-483, 2005.
68. 2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 30: 377-386, 2009.
69. Moghimi S and Andresen T: Complement-mediated tumour growth: Implications for cancer nanotechnology and nano-medicines. Mol Immunol 46: 1571-1572, 2009.
70. Korbelik M: Complement upregulation in photodynamic therapy-treated tumors: Role of Toll-like receptor pathway and NFκB. Cancer Lett 281: 232-238, 2009.
71. Visser K, Korets L and Coussens L: Early neoplastic progression is complement independent. Neoplasia 6: 1-9, 2004.
72. Chatterji B and Borlak J: A 2-DE MALDI-TOF study to identify disease regulated serum proteins in lung cancer of c-myc transgenic mice. Proteomics 9: 1044-1056, 2009.
73. Nambiar P, Boutin S, Raja R and Rosenberg D: Global gene expression profiling: a complement to conventional histopathologic analysis of neoplasia. Vet Pathol 42: 735-752, 2005.
74. Li L, Spendlove I, Morgan J and Durrant L: CD55 is over-expressed in the tumour environment. Br J Cancer 84: 80-86, 2001.
75. Ricklin D and Lambris J: Complement-targeted therapeutics. Nat Biotechnol 25: 1265-1275, 2007.
76. Zhong W, Hansen R, Li B, Cai Y, Salvador C, Moore G and Yan J: Effect of yeast-derived β-glucan in conjunction with bevacizumab for the treatment of human lung adenocarcinoma in subcutaneous and orthotopic xenograft models. J Immunother 32: 703-712, 2009.
77. Li B, Allendorf DJ, Hansen R, Marroquin J, Cramer DE, Harris CL and Yan J: Combined yeast (beta)-glucan and antitumor monoclonal antibody therapy requires C5a-mediated neutrophil chemotaxis via regulation of decay-accelerating factor CD55. Cancer Res 67: 7421-7430, 2007.
78. Chan G, Chan W and Sze D: The effects of β-glucan on human immune and cancer cells. J Hem Oncol 2: 25-35, 2009.
79. Xia Y, Vetvicka V, Yan J, Hanikyrova M, Mayadas T and Ross G: The β-glucan-binding lectin site of mouse CR3 (CD11b/CD18) and its function in generating a primed state of the receptor that mediates cytotoxic activation in response to iC3b-opsonized target cells. J Immunol 162: 2281-2290, 1999.
80. Hong F, Hansen R, Yan J, Allendorf D, Baran J, Ostroff G and Ross G: β-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells. Cancer Res 63: 9023-9031, 2003.
81. Liu J, Gunn L, Hansen R and Yan J: Combined yeast-derived β-glucan with anti-tumor monoclonal antibody for cancer immunotherapy. Exp Mol Pathol 86: 208-214, 2009.
82. Zhao W-P, Zhu B, Duan Y-Z and Chen Z-T: Neutralization of complement regulatory proteins CD55 and CD59 augments therapeutic effect of herceptin against lung carcinoma cells. Oncol Rep 21: 1405-1411, 2009.
83. Hamad I, Hunter AC, Szebeni J and Moghimi S: Poly(ethylene glycol)s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process. Mol Immunol 46: 225-232, 2008.
84. Pavlin D, Cemazar M, Kamensek U, Tozon N, Pogacnik A and Sersa G: Local and systemic antitumor effect of intratumoral and peritumoral IL-12 electrogene therapy on murine sarcoma. Cancer Biol Ther 8: 1-9, 2009.
85. Wittmann M, Zwirner J, Larsson V-A, Kirchhoff K, Begemann G, Kapp A, Götze O and Werfel T: C5a suppresses the production of IL-12 by IFN-γ-primed and lipopolysaccharide-challenged human monocytes. J Immunol 162: 6763-6769, 1999.
86. Markiewski M and Lambris J: Unwelcome complement. Cancer Res 69: 6367-6370, 2009.
87. Karp C and Wills-Karp M: Complement and IL-12: yin and yang. Microbes Infect 3: 109-119, 2001.
88. Gerard N, Lu B, Liu P, Craig S, Fujiwara Y, Okinaga S and Gerard C: An anti-inflammatory function for the complement anaphylatoxin C5a-binding protein. J Biol Chem 280: 39677-39680, 2005.
89. Scola A, Higginbottom A, Partridge L, Reid R, Woodruff T, Taylor S, Fairlie D and Monk P: The role of the N-terminal domain of the complement fragment receptor C5L2 in ligand binding. J Biol Chem 282: 3664-3671, 2007.